Alan Gilbert Goodman

Avlar Ltd. (Avlar BioVentures) is a venture capital firm founded in 1999 by Alan Goodman and Daniel Roach. The firm is headquartered in Cambridge, United Kingdom.

CeNeS Pharmaceuticals Plc engages in the discovery and development of drugs. The company was founded by Alan Gilbert Goodman in 1997 and is headquartered in Cambridge, the United Kingdom.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Proteom Ltd. used to develop pharmaceutical products. It had created computational chemistry platform to help identify and screen novel small molecule and peptide based ligands for protein targets. Proteom's ProtoBuild used to provide silico (computer-simulated) design and its ProtoScreen used to identify potential leads from a variety of commercially available compounds. Proteom Ltd. was headquartered in Comberton, EA.

Amura Holdings Ltd. was engaged in drug discovery for diseases, such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain, and malaria. The firm developed a technology platform that provided turnkey solutions for the discovery of small-molecule inhibitors against cysteine peptidases. The company was founded by Daniel James William Roach on June 6, 20005 and was headquartered in Cambridge, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.